The first is based on studies that have shown that BCMA expression in tumor cell populations is heterogeneous and that a relapse after BCMA-directed CAR T-cell therapy may be caused by the selection of clones that lack BCMA expression [20]. This evidence concerns the gene TNFRSF17 and neoplasm.